Selected category: Synthetic

Synthetic DNA has become the central component of countless scientific and technological innovations across many applications, from biopharmaceuticals to biofuels. However, research and drug development pipelines are often hindered by the cost and the length of time that it takes to obtain long sequences of DNA or multiple DNA variants. Ribbon Biolabs, based in Vienna, is addressing this issue by combining automation and adaptive algorithmic control with highly precise, optimized enzymatic synthesis.